Learn how sponsors are advancing RLT pivotal trials
Phase 3 radiopharmaceutical trials carry a lighter procedural burden per site than early-phase studies, but standing them up globally at scale – with manufacturing proximity, geomix-aligned regulatory strategy, and standardized site operations – requires planning that begins well before pivotal initiation.
If you’re planning a pivotal RLT trial or evaluating CRO partners, this session covers the decisions most directly affecting your timeline and data quality.
Originally presented at TRP Summit 2026, the full recording is now available on demand.
Unlock the recording
Enter your details below to see how industry leaders are addressing the complexities of radiopharm clinical development.
* indicates required fields
"*" indicates required fields
What you can expect to learn
Volker Wagner, MD, PhD, Chief Medical Officer, Orano Med, and Lucy Knight, PhD, RLT Program Director, Project Management, PSI CRO, will address:
Designing scalable site, participant, vendor, and supply chain strategies anchored to manufacturing facility locations before phase 3
Aligning your regulatory approach to your geomix and mitigating operational challenges to ensure optimal endpoint data collection
Applying lessons from successful RLT pivotal programs from sponsor and CRO perspectives
The people in the room
Volker Wagner, MD, PhD
Chief Medical Officer
Orano Med
Lucy Knight, PhD
RLT Program Director, Project Management
PSI CRO
